Literature DB >> 16882203

Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod.

J Utikal, A Zimpfer, A Thoelke, R Figl, R Hildenbrand, C Kettelhack, S Goerdt, D Schadendorf, S Ugurel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16882203     DOI： 10.1111/j.1365-2133.2006.07333.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.

Authors:  Kristin Turza; Lynn T Dengel; Rebecca C Harris; James W Patterson; Kevin White; William W Grosh; Craig L Slingluff
Journal:  J Cutan Pathol       Date:  2009-07-07       Impact factor: 1.587

2.  Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model.

Authors:  Eric C Kauffman; Huixian Liu; Michael J Schwartz; Douglas S Scherr
Journal:  J Oncol       Date:  2012-02-22       Impact factor: 4.375

3.  Alterations of circulating bone marrow-derived VEGFR-2+ progenitor cells in isolated limb perfusion with or without rhTNF-α.

Authors:  Kai Nowak; Nicole Jachol; Neysan Rafat; Elena Joas; Grietje Ch Beck; Peter Hohenberger
Journal:  Ann Surg Oncol       Date:  2012-09-05       Impact factor: 5.344

4.  Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy.

Authors:  Raphael Reinhard; Christoffer Gebhardt; Nolwenn Maurier; Lionel Larribère; Azadeh Orouji; Jochen Utikal
Journal:  JAAD Case Rep       Date:  2018-01-16

5.  Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.

Authors:  Hansje-Eva Teulings; Esther P M Tjin; Karina J Willemsen; Stephanie van der Kleij; Sylvia Ter Meulen; E Helen Kemp; Gabrielle Krebbers; Carel J M van Noesel; Cornelis L M C Franken; Jan W Drijfhout; Cornelis J M Melief; Ludmila Nieuweboer-Krobotova; Omgo E Nieweg; Jos A van der Hage; J P Wietze van der Veen; Germaine N Relyveld; Rosalie M Luiten
Journal:  Oncoimmunology       Date:  2018-01-15       Impact factor: 8.110
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.